董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Saqib Islam | 男 | Director | 54 | 43.05万美元 | 24.87 | 2023-05-01 |
| Richard E. Lowenthal | 男 | President and Chief Executive Officer and Director | 57 | 965.64万美元 | 1208.69 | 2023-05-01 |
| Phillip Schneider | 男 | Director | 67 | 44.05万美元 | 31.05 | 2023-05-01 |
| Rajeev Dadoo | 男 | Director | 53 | 42.55万美元 | 8.00 | 2023-05-01 |
| Michael Kelly | 男 | Director | 58 | 43.55万美元 | 35.18 | 2023-05-01 |
| Pratik Shah | -- | Director and Chairman of the Board | 53 | 未披露 | 未持股 | 2023-05-01 |
| Peter Kolchinsky | 男 | Director | 46 | 未披露 | 未持股 | 2023-05-01 |
| Brenton L. Saunders | 男 | Director | 55 | 未披露 | 未持股 | 2023-05-01 |
| Peter A. Thompson | 男 | Director | 63 | 42.30万美元 | 15.13 | 2023-05-01 |
| Peter Thompson | 男 | Director | 63 | 未披露 | 未持股 | 2023-05-01 |
| Laura Shawver | 女 | Director | 65 | 41.78万美元 | 120.37 | 2023-05-01 |
| Brenton L. Saunders | 男 | Director | 53 | 43.55万美元 | 70.46 | 2023-05-01 |
| Pratik Shah | 男 | Director and Chairman of the Board | 54 | 68.92万美元 | 490.91 | 2023-05-01 |
| Peter Kolchinsky | 男 | Director | 46 | 43.05万美元 | 1094.10 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kathleen Scott | 女 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2023-05-01 |
| Sarina Tanimoto | 女 | Chief Medical Officer | 54 | 529.05万美元 | 183.02 | 2023-05-01 |
| Richard E. Lowenthal | 男 | President and Chief Executive Officer and Director | 57 | 965.64万美元 | 1208.69 | 2023-05-01 |
| Eric Karas | 男 | Chief Commercial Officer | 51 | 22.26万美元 | 未持股 | 2023-05-01 |
| Justin Chakma | 男 | Chief Business Officer | 34 | 288.81万美元 | 59.75 | 2023-05-01 |
| Brian T. Dorsey | 男 | Chief Operating Officer | 54 | 223.51万美元 | 未持股 | 2023-05-01 |
| Alexander A. Fitzpatrick | 男 | Chief Legal Officer and Secretary | 56 | 未披露 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- Saqib Islam
-
Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School. - Saqib Islam自2018年8月起担任SpringWorks Therapeutics, Inc.的首席执行官和董事会成员。此前，自2017年8月成立以来，Islam先生一直担任SpringWorks Therapeutics, Inc.的首席财务官兼首席商务官。在加入SpringWorks之前，先生。 2016年2月至2017年8月，Islam担任Moderna Therapeutics，Inc.的首席商务官。在加入Moderna Therapeutics，Inc.之前，Islam先生自2013年2月起担任Alexion Pharmaceuticals，Inc.的执行副总裁，首席战略和投资组合官。 2016年2月，他负责执行公司的企业发展战略，并为全球运营的评估和管理做出了贡献。在加入Alexion之前，Islam先生在国际业务管理领域工作超过25年，专注于业务发展，战略决策和规划以及资本市场，曾担任摩根士丹利和瑞士信贷的董事总经理职务。伊斯兰先生拥有哥伦比亚大学法学院的学士学位，在那里他是哈伦菲斯克学者，并且是麦吉尔大学的学士学位，他是一名教师和大学学者。
- Saqib Islam has served as a member of SpringWorks Therapeutics, Inc. board of directors since July 2017. Mr. Islam has also served as the Chief Executive Officer and a member of the board of directors of Springworks Therapeutics, Inc. since August 2018. In addition, Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. From February 2016 to August 2017 Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. From February 2013 to February 2016 Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. Prior to joining Alexion, Mr. Islam served in various Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam holds a B.A. from McGill University and a J.D. from Columbia Law School.
- Richard E. Lowenthal
-
Richard E. Lowenthal曾担任Pacific-Link Regulatory Consulting and Research，Inc.的总裁，这是一家由Lowenthal先生创立的医药产品开发咨询公司，在那里他就临床开发、监管事务、质量保证、许可和投资机会提供领导和指导，包括支持Valtoco（地西泮鼻喷剂）的临床和监管开发。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Lowenthal先生曾在多家生物制药和制药公司担任过多个领导职务，包括MTG Biotherapeutics Inc.的首席执行官兼总裁；Cadence Pharmaceuticals, Inc.的法规事务和质量保证副总裁；Maxim Pharmaceuticals，Inc.的全球法规事务、质量保证和药物安全负责人；Anges、MG的法规事务和质量保证副总裁，Inc.；杨森研究基金会全球项目负责人和监管事务全球总监；Somerset Pharmaceuticals Inc.监管事务和质量保证总监；美国食品药品监督管理局神经药理药物产品司和肿瘤学和肺部药物产品司新药审查化学家。Lowenthal先生拥有佛罗里达州立大学有机化学硕士学位和圣地亚哥大学行政领导商业科学硕士学位。他曾担任美国药学科学家协会（圣地亚哥地区）前任主席，也是USP生物技术专家委员会、病毒学工作组成员，国家罕见病组织企业理事会成员，曾与多个PhRMA和ICH工作组合作。
Richard E. Lowenthal served as President of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy founded by Mr. Lowenthal, where he provided leadership and mentoring on clinical development, regulatory affairs, quality assurance, licensing and investment opportunities, including supporting the clinical and regulatory development of Valtoco (diazepam nasal spray). Prior to Pacific- Link Regulatory Consulting and Research, Inc., Mr. Lowenthal held many leadership roles at several biopharmaceutical and pharmaceutical companies that included Chief Executive Officer and President of MTG Biotherapeutics Inc.; Vice President of Regulatory Affairs and quality assurance for Cadence Pharmaceuticals, Inc.; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director of Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance for Somerset Pharmaceuticals Inc.; and New Drug Review Chemist for the U.S. Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products. Mr. Lowenthal holds an M.Sc. in organic chemistry from Florida State University and a Master's in Business Science for Executive Leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhRMA and ICH Working Groups. - Richard E. Lowenthal曾担任Pacific-Link Regulatory Consulting and Research，Inc.的总裁，这是一家由Lowenthal先生创立的医药产品开发咨询公司，在那里他就临床开发、监管事务、质量保证、许可和投资机会提供领导和指导，包括支持Valtoco（地西泮鼻喷剂）的临床和监管开发。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Lowenthal先生曾在多家生物制药和制药公司担任过多个领导职务，包括MTG Biotherapeutics Inc.的首席执行官兼总裁；Cadence Pharmaceuticals, Inc.的法规事务和质量保证副总裁；Maxim Pharmaceuticals，Inc.的全球法规事务、质量保证和药物安全负责人；Anges、MG的法规事务和质量保证副总裁，Inc.；杨森研究基金会全球项目负责人和监管事务全球总监；Somerset Pharmaceuticals Inc.监管事务和质量保证总监；美国食品药品监督管理局神经药理药物产品司和肿瘤学和肺部药物产品司新药审查化学家。Lowenthal先生拥有佛罗里达州立大学有机化学硕士学位和圣地亚哥大学行政领导商业科学硕士学位。他曾担任美国药学科学家协会（圣地亚哥地区）前任主席，也是USP生物技术专家委员会、病毒学工作组成员，国家罕见病组织企业理事会成员，曾与多个PhRMA和ICH工作组合作。
- Richard E. Lowenthal served as President of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy founded by Mr. Lowenthal, where he provided leadership and mentoring on clinical development, regulatory affairs, quality assurance, licensing and investment opportunities, including supporting the clinical and regulatory development of Valtoco (diazepam nasal spray). Prior to Pacific- Link Regulatory Consulting and Research, Inc., Mr. Lowenthal held many leadership roles at several biopharmaceutical and pharmaceutical companies that included Chief Executive Officer and President of MTG Biotherapeutics Inc.; Vice President of Regulatory Affairs and quality assurance for Cadence Pharmaceuticals, Inc.; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director of Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance for Somerset Pharmaceuticals Inc.; and New Drug Review Chemist for the U.S. Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products. Mr. Lowenthal holds an M.Sc. in organic chemistry from Florida State University and a Master's in Business Science for Executive Leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhRMA and ICH Working Groups.
- Phillip Schneider
-
自2022年11月合并完成以来，菲利普·施耐德一直担任Ars Pharmaceuticals，Inc.董事会成员。此前，Schneider先生曾于2019年5月至2022年11月担任Private ARS Pharma的董事会成员。他还自2020年12月起担任Longboard Pharmaceuticals, Inc.（纳斯达克：LBPH）的董事会成员。Schneider先生此前曾于2014年7月至2020年10月担任临床阶段生物技术产品公司Pfenex Inc.的董事。在此之前，Schneider先生曾于1987年至2003年在IDEC Pharmaceuticals Corporation担任多个职位，该公司是一家专注于治疗血液系统和自身免疫性疾病的疗法的生物制药公司，包括：1997年至2003年担任高级副总裁兼首席财务官；1992年至1997年担任财务和行政总监。在此之前，施耐德先生曾于1985年至1987年在制药公司Syntex Pharmaceuticals Corporation担任过多个管理职务，并于1982年至1984年在审计和税务咨询公司KPMG LLP担任过多个管理职务，在那里他获得了注册会计师执照。Schneider先生此前曾担任临床阶段制药公司Arena Pharmaceuticals, Inc.（纳斯达克：ARNA）的董事会成员，2008年至2018年担任生物制药公司Auspex Pharmaceuticals, Inc.（原纳斯达克：ASPX），2014年至2015年被梯瓦制药 Ltd.收购，并于2002年至2012年被Hologic Inc.收购期间担任生物技术公司Gen-Probe，Inc.的董事会成员。施耐德先生拥有加州大学戴维斯分校的生物化学学士学位和南加州大学的工商管理硕士学位。
Phillip Schneider,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Previously Mr. Schneider served on the board of directors of Private ARS Pharma from May 2019 to November 2022. He also has served on the board of directors of Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) since December 2020. Mr. Schneider previously served as a director of Pfenex Inc., a clinical-stage biotechnology products company, from July 2014 to October 2020. Prior to that, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company focused on therapies for the treatment of hematologic, and autoimmune diseases, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987, and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. Mr. Schneider previously served as a member of the board of directors at Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a clinical stage pharmaceutical company, from 2008 to 2018, Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from 2014 until its acquisition by Teva Pharmaceutical Industries Ltd. in 2015, and served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 until its acquisition by Hologic Inc. in 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California. - 自2022年11月合并完成以来，菲利普·施耐德一直担任Ars Pharmaceuticals，Inc.董事会成员。此前，Schneider先生曾于2019年5月至2022年11月担任Private ARS Pharma的董事会成员。他还自2020年12月起担任Longboard Pharmaceuticals, Inc.（纳斯达克：LBPH）的董事会成员。Schneider先生此前曾于2014年7月至2020年10月担任临床阶段生物技术产品公司Pfenex Inc.的董事。在此之前，Schneider先生曾于1987年至2003年在IDEC Pharmaceuticals Corporation担任多个职位，该公司是一家专注于治疗血液系统和自身免疫性疾病的疗法的生物制药公司，包括：1997年至2003年担任高级副总裁兼首席财务官；1992年至1997年担任财务和行政总监。在此之前，施耐德先生曾于1985年至1987年在制药公司Syntex Pharmaceuticals Corporation担任过多个管理职务，并于1982年至1984年在审计和税务咨询公司KPMG LLP担任过多个管理职务，在那里他获得了注册会计师执照。Schneider先生此前曾担任临床阶段制药公司Arena Pharmaceuticals, Inc.（纳斯达克：ARNA）的董事会成员，2008年至2018年担任生物制药公司Auspex Pharmaceuticals, Inc.（原纳斯达克：ASPX），2014年至2015年被梯瓦制药 Ltd.收购，并于2002年至2012年被Hologic Inc.收购期间担任生物技术公司Gen-Probe，Inc.的董事会成员。施耐德先生拥有加州大学戴维斯分校的生物化学学士学位和南加州大学的工商管理硕士学位。
- Phillip Schneider,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Previously Mr. Schneider served on the board of directors of Private ARS Pharma from May 2019 to November 2022. He also has served on the board of directors of Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) since December 2020. Mr. Schneider previously served as a director of Pfenex Inc., a clinical-stage biotechnology products company, from July 2014 to October 2020. Prior to that, Mr. Schneider held various positions with IDEC Pharmaceuticals Corporation, a biopharmaceutical company focused on therapies for the treatment of hematologic, and autoimmune diseases, from 1987 to 2003, including: Senior Vice President and Chief Financial Officer from 1997 to 2003; and Director of Finance and Administration from 1992 to 1997. Prior to that, Mr. Schneider held various management positions at Syntex Pharmaceuticals Corporation, a pharmaceutical company, from 1985 to 1987, and KPMG LLP, an audit and tax advisory firm, from 1982 to 1984, where he attained his CPA license. Mr. Schneider previously served as a member of the board of directors at Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), a clinical stage pharmaceutical company, from 2008 to 2018, Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from 2014 until its acquisition by Teva Pharmaceutical Industries Ltd. in 2015, and served as a member of the board of directors of Gen-Probe, Inc., a biotechnology company, from 2002 until its acquisition by Hologic Inc. in 2012. Mr. Schneider holds a B.S. in Biochemistry from the University of California, Davis and an M.B.A. from the University of Southern California.
- Rajeev Dadoo
-
Rajeev Dadoo，自2022年11月合并完成以来一直担任Ars Pharmaceuticals，Inc.董事会成员。Dadoo博士此前曾于2021年8月至2022年11月担任Private ARS Pharma的董事会成员。自2020年9月起，Dadoo博士担任SR One Capital Management，L.P.的管理合伙人。Dadoo博士此前是葛兰素史克全资子公司S.R. One，Limited的合伙人，他于2004年加入该公司。他是Kauffman Fellows Program的校友。他之前担任的职务包括在葛兰素史克（GlaxoSmithKline）的Competitive Excellence集团工作，葛兰素史克是一家全球性的医疗保健公司，从事医药、疫苗和消费类医疗保健产品的研究、开发和制造，参与多个全球项目，并在生物技术公司基因泰克从事技术和临床开发工作。他还曾分别在面向生命科学研究和临床诊断市场的专用技术产品的美国开发商和制造商Bio-Rad Laboratories, Inc.（NYSE：BIO）以及生物技术公司Genome Therapeutics Corp.担任产品开发和业务开发职务。Dadoo博士拥有诺克斯学院化学和数学学士学位、斯坦福大学化学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
Rajeev Dadoo,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Dadoo previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Since September 2020, Dr. Dadoo has served as a managing partner of SR One Capital Management, L.P. Dr. Dadoo was previously a Partner at S.R. One, Limited, a wholly owned subsidiary of GlaxoSmithKline, which he joined in 2004. He is an alum of the Kauffman Fellows Program. His prior roles have included working in the Competitive Excellence group at GlaxoSmithKline, a global healthcare company which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products, on various global projects and at Genentech, Inc., a biotechnology company, in technology and clinical development. He has also held product development and business development roles at Bio-Rad Laboratories, Inc. (NYSE: BIO), an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets, and Genome Therapeutics Corp., a biotechnology company, respectively. Dr. Dadoo holds a BA degree in Chemistry and Mathematics from Knox College, a Ph.D. in Chemistry from Stanford University, and an M.B.A. from the Wharton School of the University of Pennsylvania. - Rajeev Dadoo，自2022年11月合并完成以来一直担任Ars Pharmaceuticals，Inc.董事会成员。Dadoo博士此前曾于2021年8月至2022年11月担任Private ARS Pharma的董事会成员。自2020年9月起，Dadoo博士担任SR One Capital Management，L.P.的管理合伙人。Dadoo博士此前是葛兰素史克全资子公司S.R. One，Limited的合伙人，他于2004年加入该公司。他是Kauffman Fellows Program的校友。他之前担任的职务包括在葛兰素史克（GlaxoSmithKline）的Competitive Excellence集团工作，葛兰素史克是一家全球性的医疗保健公司，从事医药、疫苗和消费类医疗保健产品的研究、开发和制造，参与多个全球项目，并在生物技术公司基因泰克从事技术和临床开发工作。他还曾分别在面向生命科学研究和临床诊断市场的专用技术产品的美国开发商和制造商Bio-Rad Laboratories, Inc.（NYSE：BIO）以及生物技术公司Genome Therapeutics Corp.担任产品开发和业务开发职务。Dadoo博士拥有诺克斯学院化学和数学学士学位、斯坦福大学化学博士学位和宾夕法尼亚大学沃顿商学院工商管理硕士学位。
- Rajeev Dadoo,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Dadoo previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Since September 2020, Dr. Dadoo has served as a managing partner of SR One Capital Management, L.P. Dr. Dadoo was previously a Partner at S.R. One, Limited, a wholly owned subsidiary of GlaxoSmithKline, which he joined in 2004. He is an alum of the Kauffman Fellows Program. His prior roles have included working in the Competitive Excellence group at GlaxoSmithKline, a global healthcare company which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products, on various global projects and at Genentech, Inc., a biotechnology company, in technology and clinical development. He has also held product development and business development roles at Bio-Rad Laboratories, Inc. (NYSE: BIO), an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets, and Genome Therapeutics Corp., a biotechnology company, respectively. Dr. Dadoo holds a BA degree in Chemistry and Mathematics from Knox College, a Ph.D. in Chemistry from Stanford University, and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Michael Kelly
-
Michael Kelly，自2022年11月合并完成后一直担任Ars Pharmaceuticals，Inc.董事会成员。Kelly先生此前曾于2019年5月至2022年11月担任Private ARS Pharma的董事会成员。2016年3月至2019年6月，Kelly先生担任Adapt Pharma，Inc.的美国业务总裁，该公司开发并商业化了NARCAN （盐酸纳洛酮）鼻喷雾剂。从2013年12月到2016年3月，凯利先生担任Covis Pharmaceuticals，Inc.的首席执行官和董事，该公司是一家专注于为危及生命的疾病和慢性疾病患者提供治疗解决方案的制药公司。Kelly先生还是一家专业制药公司Azur Pharma Limited创始管理团队的成员，后来在进行战略合并后，担任生物制药公司爵士制药 PLC（纳斯达克：JAZZ）的销售和营销高级副总裁。在任职Azur Pharma之前，他曾在生物制药公司Guilford Pharmaceuticals Inc.担任商业运营副总裁，在致力于开发和商业化解决严重疾病的产品的生物技术公司ViroPharma Incorporated担任销售和营销副总裁，并在制药公司TAP Pharmaceuticals Inc.担任过各种商业和医疗职务。Kelly先生拥有新泽西学院工商管理理学学士学位和莱德大学工商管理硕士学位。
Michael Kelly,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Mr. Kelly previously served on the board of directors of Private ARS Pharma from May 2019 to November 2022. From March 2016 to June 2019, Mr. Kelly served as President of U.S. Operations for Adapt Pharma, Inc., which developed and commercialized NARCAN (naloxone HCl) Nasal Spray. From December 2013 to March 2016, Mr. Kelly served as the Chief Executive Officer and a director of Covis Pharmaceuticals, Inc., a pharmaceutical company focused on therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Mr. Kelly was also a member of the founding management team of Azur Pharma Limited, a specialty pharmaceutical company, and later, following a strategic merger, served as the Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals plc (Nasdaq: JAZZ), biopharmaceutical company. Prior to his tenure at Azur Pharma, he served as Vice President of Commercial Operations at Guilford Pharmaceuticals Inc., a biopharmaceutical company, Vice President of Sales and Marketing at ViroPharma Incorporated, biotechnology company dedicated to the development and commercialization of products that address serious diseases, and held various commercial and medical roles at TAP Pharmaceuticals Inc., a pharmaceutical company. Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University. - Michael Kelly，自2022年11月合并完成后一直担任Ars Pharmaceuticals，Inc.董事会成员。Kelly先生此前曾于2019年5月至2022年11月担任Private ARS Pharma的董事会成员。2016年3月至2019年6月，Kelly先生担任Adapt Pharma，Inc.的美国业务总裁，该公司开发并商业化了NARCAN （盐酸纳洛酮）鼻喷雾剂。从2013年12月到2016年3月，凯利先生担任Covis Pharmaceuticals，Inc.的首席执行官和董事，该公司是一家专注于为危及生命的疾病和慢性疾病患者提供治疗解决方案的制药公司。Kelly先生还是一家专业制药公司Azur Pharma Limited创始管理团队的成员，后来在进行战略合并后，担任生物制药公司爵士制药 PLC（纳斯达克：JAZZ）的销售和营销高级副总裁。在任职Azur Pharma之前，他曾在生物制药公司Guilford Pharmaceuticals Inc.担任商业运营副总裁，在致力于开发和商业化解决严重疾病的产品的生物技术公司ViroPharma Incorporated担任销售和营销副总裁，并在制药公司TAP Pharmaceuticals Inc.担任过各种商业和医疗职务。Kelly先生拥有新泽西学院工商管理理学学士学位和莱德大学工商管理硕士学位。
- Michael Kelly,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Mr. Kelly previously served on the board of directors of Private ARS Pharma from May 2019 to November 2022. From March 2016 to June 2019, Mr. Kelly served as President of U.S. Operations for Adapt Pharma, Inc., which developed and commercialized NARCAN (naloxone HCl) Nasal Spray. From December 2013 to March 2016, Mr. Kelly served as the Chief Executive Officer and a director of Covis Pharmaceuticals, Inc., a pharmaceutical company focused on therapeutic solutions for patients with life-threatening conditions and chronic illnesses. Mr. Kelly was also a member of the founding management team of Azur Pharma Limited, a specialty pharmaceutical company, and later, following a strategic merger, served as the Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals plc (Nasdaq: JAZZ), biopharmaceutical company. Prior to his tenure at Azur Pharma, he served as Vice President of Commercial Operations at Guilford Pharmaceuticals Inc., a biopharmaceutical company, Vice President of Sales and Marketing at ViroPharma Incorporated, biotechnology company dedicated to the development and commercialization of products that address serious diseases, and held various commercial and medical roles at TAP Pharmaceuticals Inc., a pharmaceutical company. Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University.
- Pratik Shah
-
自2022年11月合并完成以来，Pratik Shah一直担任Ars Pharmaceuticals，Inc.董事会成员和Ars Pharmaceuticals，Inc.主席。Shah博士此前曾于2016年4月至2022年11月担任Private ARS Pharma的董事会成员，并于2018年9月被任命为其首任董事会主席。Shah博士还自2017年12月起担任生物技术公司Design Therapeutics, Inc.（纳斯达克：DSGN）的执行主席和董事会成员，自2018年8月起担任MarlinSpike Group，LLC总裁，并于2015年6月至2020年10月担任MarlinSpike Group Inc.总裁。Shah博士于2018年10月至2020年1月被赛诺菲 S.A.收购之前，曾担任临床阶段生物技术公司Synthorx, Inc.（前身为纳斯达克：THOR）的董事会主席。Shah博士还曾于2013年10月至2015年5月被梯瓦制药 Ltd.收购之前，担任生物制药公司Auspex Pharmaceuticals, Inc.（原纳斯达克：TERM3）的总裁兼首席执行官和董事会主席。从2004年到2014年，他是Thomas，McNerney & Partners的合伙人，这是一家医疗保健风险投资公司。Shah博士拥有加州大学欧文分校的生物科学学士学位，以及芝加哥大学的生物化学和分子生物学博士学位和金融硕士学位。
Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago. - 自2022年11月合并完成以来，Pratik Shah一直担任Ars Pharmaceuticals，Inc.董事会成员和Ars Pharmaceuticals，Inc.主席。Shah博士此前曾于2016年4月至2022年11月担任Private ARS Pharma的董事会成员，并于2018年9月被任命为其首任董事会主席。Shah博士还自2017年12月起担任生物技术公司Design Therapeutics, Inc.（纳斯达克：DSGN）的执行主席和董事会成员，自2018年8月起担任MarlinSpike Group，LLC总裁，并于2015年6月至2020年10月担任MarlinSpike Group Inc.总裁。Shah博士于2018年10月至2020年1月被赛诺菲 S.A.收购之前，曾担任临床阶段生物技术公司Synthorx, Inc.（前身为纳斯达克：THOR）的董事会主席。Shah博士还曾于2013年10月至2015年5月被梯瓦制药 Ltd.收购之前，担任生物制药公司Auspex Pharmaceuticals, Inc.（原纳斯达克：TERM3）的总裁兼首席执行官和董事会主席。从2004年到2014年，他是Thomas，McNerney & Partners的合伙人，这是一家医疗保健风险投资公司。Shah博士拥有加州大学欧文分校的生物科学学士学位，以及芝加哥大学的生物化学和分子生物学博士学位和金融硕士学位。
- Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago.
- Peter Kolchinsky
-
Peter Kolchinsky，自2022年11月合并完成后一直在Ars Pharmaceuticals，Inc.董事会任职。Kolchinsky博士此前曾于2021年8月至2022年11月担任Private ARS Pharma的董事会成员。Kolchinsky博士在医疗保健投资方面拥有20多年的经验，是RA Capital Management，L.P.的创始人和管理合伙人。RA Capital Management是一家多阶段投资管理公司，致力于以证据为基础投资于正在开发药物、医疗设备、诊断和研究工具的公共和私营医疗保健和生命科学公司。Kolchinsky博士还自2021年3月起在疫苗开发公司ICOSAVAX，Inc.（纳斯达克：ICVX）的董事会任职，自2015年1月起在专注于为患有严重基因定义疾病的患者提供疗法的生物技术公司WAVE Life Sciences，Ltd.（WVE）的董事会任职，此外还在多家私营公司任职。Kolchinsky博士此前是Dicerna Pharmaceuticals, Inc.（纳斯达克：DRNA）的董事会成员，2013年7月至2019年12月，Forma Therapeutics Holdings, Inc.，Inc.（前身为纳斯达克：FMTX），2019年12月至2022年10月，Synthorx, Inc.,2018年5月至2020年1月，TERM5（前身为纳斯达克：THOR），均为上市药企。Kolchinsky博士还曾在美国国家科学院全球科学与技术委员会任职，著有《伟大的美国药物交易》和《生物技术初创公司的企业家指南》。他创立了非营利组织No Patient Left Behind，以倡导医疗保健改革，以解决可负担性问题并促进持续的生物医药创新。Kolchinsky博士拥有康奈尔大学学士学位和哈佛大学病毒学博士学位。
Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-efined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University. - Peter Kolchinsky，自2022年11月合并完成后一直在Ars Pharmaceuticals，Inc.董事会任职。Kolchinsky博士此前曾于2021年8月至2022年11月担任Private ARS Pharma的董事会成员。Kolchinsky博士在医疗保健投资方面拥有20多年的经验，是RA Capital Management，L.P.的创始人和管理合伙人。RA Capital Management是一家多阶段投资管理公司，致力于以证据为基础投资于正在开发药物、医疗设备、诊断和研究工具的公共和私营医疗保健和生命科学公司。Kolchinsky博士还自2021年3月起在疫苗开发公司ICOSAVAX，Inc.（纳斯达克：ICVX）的董事会任职，自2015年1月起在专注于为患有严重基因定义疾病的患者提供疗法的生物技术公司WAVE Life Sciences，Ltd.（WVE）的董事会任职，此外还在多家私营公司任职。Kolchinsky博士此前是Dicerna Pharmaceuticals, Inc.（纳斯达克：DRNA）的董事会成员，2013年7月至2019年12月，Forma Therapeutics Holdings, Inc.，Inc.（前身为纳斯达克：FMTX），2019年12月至2022年10月，Synthorx, Inc.,2018年5月至2020年1月，TERM5（前身为纳斯达克：THOR），均为上市药企。Kolchinsky博士还曾在美国国家科学院全球科学与技术委员会任职，著有《伟大的美国药物交易》和《生物技术初创公司的企业家指南》。他创立了非营利组织No Patient Left Behind，以倡导医疗保健改革，以解决可负担性问题并促进持续的生物医药创新。Kolchinsky博士拥有康奈尔大学学士学位和哈佛大学病毒学博士学位。
- Peter Kolchinsky,has served on Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. Dr. Kolchinsky previously served on the board of directors of Private ARS Pharma from August 2021 to November 2022. Dr. Kolchinsky has more than 20 years of experience in healthcare investing and is the Founder of and a Managing Partner at RA Capital Management, L.P. RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, diagnostics and research tools. Dr. Kolchinsky has also served on the boards of directors of ICOSAVAX, Inc. (Nasdaq: ICVX), a vaccine development company, since March 2021, and WAVE Life Sciences, Ltd. (Nasdaq: WVE), a biotechnology company focused on delivering therapies for patients with serious, genetically-efined diseases, since January 2015, in addition to a number of private companies. Dr. Kolchinsky was previously a member of the board of directors of Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), from July 2013 to December 2019, Forma Therapeutics Holdings, Inc. (formerly Nasdaq: FMTX), from December 2019 to October 2022 and Synthorx, Inc. (formerly Nasdaq: THOR), from May 2018 to January 2020, all public pharmaceutical companies. Dr. Kolchinsky also served on the Board of Global Science and Technology for the National Academy of Sciences, and is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup". He founded the non-profit No Patient Left Behind to advocate for healthcare reforms that would solve affordability and promote continued biomedical innovation. Dr. Kolchinsky holds a BA from Cornell University and a Ph.D. in Virology from Harvard University.
- Brenton L. Saunders
-
Brenton L. Saunders，自2022年11月合并完成后一直担任Ars Pharmaceuticals，Inc.董事会成员。此前，他曾于2021年5月至2022年11月担任Private ARS Pharma的董事会成员。Saunders先生自2020年7月起担任美容健康公司The Beauty Health Company（纳斯达克：SKIN）（前身为Vesper Healthcare Acquisition Corp.）的董事会执行主席。Saunders先生还曾于2020年7月至2021年5月担任特殊目的收购公司Vesper Healthcare Acquisition Corp.的总裁兼首席执行官。在被艾伯维公司（纽约证券交易所代码：ABBY）收购之前，桑德斯先生曾担任Allergan plc（原纽约证券交易所代码：AGN）的董事长（2016年10月至2020年5月）和总裁兼首席执行官（2014年7月至2020年5月），该公司是一家专注于医疗美容、眼科护理、中枢神经系统和胃肠病学的制药公司。在此之前，桑德斯曾担任Forest Laboratories Inc.（前身为NYSE：FRX）的首席执行官，该公司是一家专注于中枢神经和心血管系统治疗领域的制药公司，在2014年与Actavis Plc（前身为NYSE：ACT）合并之前，他一直担任这一职务，Actavis Plc（前身为NYSE：ACT）是一家专注于收购、开发、制造和营销品牌药品、仿制药和非处方药以及生物产品的全球制药公司。与阿特维斯合并后，桑德斯于2015年被任命为合并后业务的首席执行官。从2010年3月到2013年8月，桑德斯先生担任眼健康产品公司Bausch + Lomb公司的首席执行官，直到2013年被Valeant收购。Saunders先生目前担任全球电信公司思科公司（纳斯达克：CSCO）和生物制药公司BridgeBio Pharma Inc.（纳斯达克：BBIO）的董事。他也是商业委员会的成员。Saunders先生拥有匹兹堡大学的文学学士学位、天普大学法学院的法学博士学位以及天普大学商学院的工商管理硕士学位。
Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business. - Brenton L. Saunders，自2022年11月合并完成后一直担任Ars Pharmaceuticals，Inc.董事会成员。此前，他曾于2021年5月至2022年11月担任Private ARS Pharma的董事会成员。Saunders先生自2020年7月起担任美容健康公司The Beauty Health Company（纳斯达克：SKIN）（前身为Vesper Healthcare Acquisition Corp.）的董事会执行主席。Saunders先生还曾于2020年7月至2021年5月担任特殊目的收购公司Vesper Healthcare Acquisition Corp.的总裁兼首席执行官。在被艾伯维公司（纽约证券交易所代码：ABBY）收购之前，桑德斯先生曾担任Allergan plc（原纽约证券交易所代码：AGN）的董事长（2016年10月至2020年5月）和总裁兼首席执行官（2014年7月至2020年5月），该公司是一家专注于医疗美容、眼科护理、中枢神经系统和胃肠病学的制药公司。在此之前，桑德斯曾担任Forest Laboratories Inc.（前身为NYSE：FRX）的首席执行官，该公司是一家专注于中枢神经和心血管系统治疗领域的制药公司，在2014年与Actavis Plc（前身为NYSE：ACT）合并之前，他一直担任这一职务，Actavis Plc（前身为NYSE：ACT）是一家专注于收购、开发、制造和营销品牌药品、仿制药和非处方药以及生物产品的全球制药公司。与阿特维斯合并后，桑德斯于2015年被任命为合并后业务的首席执行官。从2010年3月到2013年8月，桑德斯先生担任眼健康产品公司Bausch + Lomb公司的首席执行官，直到2013年被Valeant收购。Saunders先生目前担任全球电信公司思科公司（纳斯达克：CSCO）和生物制药公司BridgeBio Pharma Inc.（纳斯达克：BBIO）的董事。他也是商业委员会的成员。Saunders先生拥有匹兹堡大学的文学学士学位、天普大学法学院的法学博士学位以及天普大学商学院的工商管理硕士学位。
- Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
- Peter A. Thompson
-
Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter A. Thompson，自2022年2月起担任Sionna Therapeutics，Inc.董事会成员。Thompson博士是投资公司OrbiMed Advisors LLC的成员，自2010年以来，他在OrbiMed Advisors LLC担任过各种职责日益增加的角色，包括2013年至2021年担任合伙人。Thompson博士目前在ARS Pharmaceuticals Inc.（前身为Silverback Therapeutics, Inc.）（NASDAQ：SPRY）董事会任职，自2016年4月起任职，Corvus Pharmaceuticals, Inc. Pharmaceuticals，Inc.（NASDAQ：CRVS），自2014年11月起任职，Edgewise Therapeutics, Inc.（NASDAQ：EWTX），自2017年5月起任职，还曾任职于多家私营公司。此前，Thompson博士曾在Alpine Immune Sciences, Inc.（纳斯达克股票代码：ALPN）、Decibel Therapeutics, Inc.（纳斯达克股票代码：DBTX）、Janux Therapeutics, Inc.（纳斯达克股票代码：JANX）、TERMVPMV Pharmaceuticals，Inc.（纳斯达克股票代码：PMVP）、Prevail Therapeutics Inc.（纳斯达克股票代码：PRVL）和Synthorx, Inc.的董事会任职，直至其被赛诺菲收购。Thompson博士此前曾在Trubion Pharmaceuticals，Inc.、Chiron Corporation和碧迪医疗公司担任行政领导职务。Thompson博士还是华盛顿大学神经外科的附属教授。此外，Thompson博士还拥有布朗大学分子生物学和数学理学学士学位和布朗大学医学院医学博士学位。
- Peter A. Thompson,has served as a member of Sionna Therapeutics, Inc. board of directors since February 2022. Dr. Thompson is a member at OrbiMed Advisors LLC, an investment firm, where he has served in various roles of increasing responsibility since 2010, including as Partner from 2013 to 2021. Dr. Thompson currently serves on the boards of directors of ARS Pharmaceuticals Inc. (formerly Silverback Therapeutics, Inc.) (NASDAQ: SPRY), since April 2016, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), since November 2014, and Edgewise Therapeutics, Inc. (NASDAQ: EWTX), since May 2017, as well as several private companies. Previously, Dr. Thompson served on the boards of directors of Alpine Immune Sciences, Inc. (NASDAQ: ALPN), Decibel Therapeutics, Inc. (NASDAQ: DBTX), Janux Therapeutics, Inc. (NASDAQ: JANX), PMV Pharmaceuticals, Inc. (NASDAQ: PMVP), Prevail Therapeutics Inc. (NASDAQ: PRVL) and Synthorx, Inc., until its acquisition by Sanofi. Dr. Thompson previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation and Becton, Dickinson and Company. Dr. Thompson is also an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Peter Thompson
-
Peter Thompson, M.D.，自2011年6月以来，是本公司的一位董事会成员。自2013年9月以来，是一家医疗投资公司- Orbimed Advisors有限责任公司的私人股本合伙人，此前他曾于2010年8月-2013年9月期间在该公司担任投资合伙人。2002年，他联合创立了Trubion Pharmaceuticals，并担任该公司的首席执行官和董事长一直到2009年。Thompson博士是Chiron公司的Chiron Informatics前副总裁和总经理，曾在Becton、Dickinson和该公司担任各种行政管理职位，包括研究和科技部门副总裁。他目前分别是Anthera Pharmaceuticals股份有限公司、Response Biomedical股份有限公司、Cleave Biosciences股份有限公司的一位董事，并且是Principia Biosciences股份有限公司的联合创始人。他是 Ernst & Young LLP的一位年度企业家奖项获得者、许多项专利的发明者、一位经董事会认证的内科和肿瘤学家，以及是Washington大学的神经外科学兼职教授。他曾在美国国家癌症研究所（National Cancer Institute）任职，曾在耶鲁大学（Yale University）参加内科医学培训，以及从Brown大学获得他的医学博士学位。
Peter Thompson co-founded the Company and has served as a member of Edgewise Therapeutics, Inc.'s board of directors since May 2017. He has also served as chairman of Edgewise Therapeutics, Inc.'s board of directors since August 2017. Dr. Thompson is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson currently serves on the board of directors of several public companies, including Alpine Immune Sciences, Inc., Corvus Pharmaceuticals, Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics Inc., and Silverback Therapeutics, Inc. Dr. Thompson has previously served on the board of directors of Adaptimmune Therapeutics PLC, Principia Biopharma Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson has co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter Thompson, M.D.，自2011年6月以来，是本公司的一位董事会成员。自2013年9月以来，是一家医疗投资公司- Orbimed Advisors有限责任公司的私人股本合伙人，此前他曾于2010年8月-2013年9月期间在该公司担任投资合伙人。2002年，他联合创立了Trubion Pharmaceuticals，并担任该公司的首席执行官和董事长一直到2009年。Thompson博士是Chiron公司的Chiron Informatics前副总裁和总经理，曾在Becton、Dickinson和该公司担任各种行政管理职位，包括研究和科技部门副总裁。他目前分别是Anthera Pharmaceuticals股份有限公司、Response Biomedical股份有限公司、Cleave Biosciences股份有限公司的一位董事，并且是Principia Biosciences股份有限公司的联合创始人。他是 Ernst & Young LLP的一位年度企业家奖项获得者、许多项专利的发明者、一位经董事会认证的内科和肿瘤学家，以及是Washington大学的神经外科学兼职教授。他曾在美国国家癌症研究所（National Cancer Institute）任职，曾在耶鲁大学（Yale University）参加内科医学培训，以及从Brown大学获得他的医学博士学位。
- Peter Thompson co-founded the Company and has served as a member of Edgewise Therapeutics, Inc.'s board of directors since May 2017. He has also served as chairman of Edgewise Therapeutics, Inc.'s board of directors since August 2017. Dr. Thompson is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson currently serves on the board of directors of several public companies, including Alpine Immune Sciences, Inc., Corvus Pharmaceuticals, Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics Inc., and Silverback Therapeutics, Inc. Dr. Thompson has previously served on the board of directors of Adaptimmune Therapeutics PLC, Principia Biopharma Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson has co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson holds a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Laura Shawver
-
Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors. - Laura Shawver自2020年4月以来一直担任我们的首席执行官兼董事会成员。Shawver博士还自2017年3月起担任RelayTherapeutics，Inc.董事会成员，自2020年3月起担任Nkarta，Inc.董事会成员。此前，Shawver博士曾于2017年11月至2020年1月被赛诺菲收购期间担任Synthorx，Inc.的总裁兼首席执行官兼董事会成员。2011年9月至2018年4月，她担任Cleave Biosciences的首席执行官兼董事会成员。从2010年10月到2011年8月，她曾担任5AM Ventures公司的常驻企业家，此前曾任职Phenomix Science公司、Sugen公司、Berlex Biosciences公司（原名Triton Biosciences公司）。Shawver博士拥有爱荷华大学（University of Iowa）的微生物学学士学位和药理学博士学位。
- Laura Shawver,has served as a member of board of directors since March 2017. Dr. Shawver will not stand for re-election as a Class II director at the Annual Meeting. Since September 2022, Dr. Shawver has served as the President and Chief Executive Officer of Capstan Therapeutics, Inc., a privately held biotechnology company, and a member of its board of directors. From April 2020 until its acquisition by ARS Pharmaceuticals, Inc. in 2022, Dr. Shawver was President and Chief Executive Officer of Silverback Therapeutics, Inc., a publicly traded biotechnology company. Dr. Shawver has served as a member of the board of directors of ARS Pharmaceuticals, Inc. since November 2022. From November 2017 until its acquisition by Sanofi, Inc. in January 2020, Dr. Shawver served as the President and Chief Executive Officer of Synthorx, Inc., a publicly traded biotechnology company, and as a member of its board of directors. From March 2020 to June 2023, Dr. Shawver also served as a member of the board of directors of publicly-traded biotechnology company, Nkarta, Inc. She also serves as a member of the board of directors of Bright Peak Therapeutics and Dovetail Therapeutics, both of which are privately held biotechnology companies. Dr. Shawver previously served as Chief Executive Officer of Cleave Therapeutics, Inc., Entrepreneur in Residence for 5AM Ventures, Chief Executive Officer of Phenomix Corporation and President of Sugen, Inc. Dr. Shawver holds a B.S. in microbiology and a Ph.D. in pharmacology from the University of Iowa. Dr. Shawver's extensive experience leading companies in the pharmaceutical industry qualifies her to serve on board of directors.
- Brenton L. Saunders
-
Brenton L. Saunders，自2010三月起担任博士伦首席执行官和董事。此前，2003-2010，他担任先灵葆雅的高级执行官，最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并，及160亿美元收购欧加农生物公司这两项并购业务，他都是负责人。在加入先灵葆雅之前，2000-2003，他担任普华永道的董事，及合规经营咨询部的负责人。在这之前，1998-1999，他是Coventry Health Carer的首席风险官；1995，他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯，担任首席合规官。除了担任博士伦董事，他还在ElectroCore LLC，the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会，美国药物研究和制造商协会，和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位，天普大学商学院工商管理硕士学位，天普大学法学院法学博士学位。
Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business. - Brenton L. Saunders，自2010三月起担任博士伦首席执行官和董事。此前，2003-2010，他担任先灵葆雅的高级执行官，最近的职务是全球消费者保健总裁。先灵葆雅与默克公司的合并，及160亿美元收购欧加农生物公司这两项并购业务，他都是负责人。在加入先灵葆雅之前，2000-2003，他担任普华永道的董事，及合规经营咨询部的负责人。在这之前，1998-1999，他是Coventry Health Carer的首席风险官；1995，他成为Health Care Compliance Association的合伙人。他在托马斯杰弗逊大学卫生系统开始职业生涯，担任首席合规官。除了担任博士伦董事，他还在ElectroCore LLC，the Overlook Hospital Foundation出任董事。他还是美国心脏协会纽约分会的前主席。他还是联邦储备银行纽约州北部地区咨询委员会，美国药物研究和制造商协会，和商业协会的成员。他担任着匹兹堡大学理事会成员。他获得了匹兹堡大学的学士学位，天普大学商学院工商管理硕士学位，天普大学法学院法学博士学位。
- Brenton L. Saunders,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors since the closing of the Merger in November 2022. He previously served on the board of directors of Private ARS Pharma from May 2021 to November 2022. Mr. Saunders has served as the Executive Chairman of the board of directors of The Beauty Health Company (Nasdaq: SKIN) (formerly Vesper Healthcare Acquisition Corp.), a beauty health company, since July 2020. Mr. Saunders also served as the President and Chief Executive Officer of Vesper Healthcare Acquisition Corp., a special purpose acquisition company, from July 2020 to May 2021. Until its acquisition by AbbVie Inc. (NYSE: ABBY), Mr. Saunders served as Chairman (October 2016 to May 2020) and President and Chief Executive Officer (July 2014 to May 2020) of Allergan plc (formerly NYSE: AGN), a pharmaceutical company that focuses on medical aesthetics, eye care, central nervous system, and gastroenterology. Prior to that,Mr. Saunders served as Chief Executive Officer of Forest Laboratories Inc. (formerly NYSE: FRX), a pharmaceutical company focused on therapeutic areas of the central nervous and cardiovascular systems, a role he held until its merger with Actavis Plc (formerly NYSE: ACT), a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products, in 2014. Following the merger with Actavis, Mr. Saunders was named Chief Executive Officer of the combined business in 2015. From March 2010 until August 2013, Mr. Saunders served as Chief Executive Officer of Bausch + Lomb Incorporated, an eye health products company, until its acquisition by Valeant in 2013. Mr. Saunders currently serves as a director of Cisco Systems, Inc. (Nasdaq: CSCO), a global telecommunications company, and BridgeBio Pharma Inc. (Nasdaq: BBIO), a biopharmaceutical company. He is also a member of The Business Council. Mr. Saunders holds a Bachelor of Arts degree from the University of Pittsburgh, a Juris Doctor degree from the Temple University School of Law, and an M.B.A. from the Temple University School of Business.
- Pratik Shah
-
2013年10月以来，Pratik Shah 担任Auspex Pharmaceuticals, Inc.的总裁兼首席执行官。2007年6月以来，他是Auspex Pharmaceuticals, Inc.董事会的成员。从2008年9月到2013年10月他担任Auspex Pharmaceuticals, Inc.董事会主席。自2004年以来他是 Thomas, McNerney & Partners 风险资本公司的合伙人。加入Thomas，McNerney & Partners之前，他创办了Kalypsys公司，一家私人临床阶段制药公司，从2001年到2004年，他担任首席商务官负责公司的总体战略、业务发展和运营。创办Kalypsys之前，从1999年到2001年，他是McKinsey & Company工作，一家咨询公司，他负责生物技术和风险资本项目。加入McKinsey & Company之前，他创办NephRx Corporation，主攻研究肾脏疾病的治疗蛋白质的一家新创公司，从1997年到1999年，在那里他担任业务副总裁。除了担任Auspex Pharmaceuticals, Inc.的董事外，他当前在Ocera Therapeutics担任董事，一家上市临床阶段生物制药公司。以及其他私人公司的董事：Cebix Incorporated 和 SGB。他从加州大学欧文分校获得生物科学学士学位，从芝加哥大学获得生物化学和分子生物学博士学位和金融MBA。
Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago. - 2013年10月以来，Pratik Shah 担任Auspex Pharmaceuticals, Inc.的总裁兼首席执行官。2007年6月以来，他是Auspex Pharmaceuticals, Inc.董事会的成员。从2008年9月到2013年10月他担任Auspex Pharmaceuticals, Inc.董事会主席。自2004年以来他是 Thomas, McNerney & Partners 风险资本公司的合伙人。加入Thomas，McNerney & Partners之前，他创办了Kalypsys公司，一家私人临床阶段制药公司，从2001年到2004年，他担任首席商务官负责公司的总体战略、业务发展和运营。创办Kalypsys之前，从1999年到2001年，他是McKinsey & Company工作，一家咨询公司，他负责生物技术和风险资本项目。加入McKinsey & Company之前，他创办NephRx Corporation，主攻研究肾脏疾病的治疗蛋白质的一家新创公司，从1997年到1999年，在那里他担任业务副总裁。除了担任Auspex Pharmaceuticals, Inc.的董事外，他当前在Ocera Therapeutics担任董事，一家上市临床阶段生物制药公司。以及其他私人公司的董事：Cebix Incorporated 和 SGB。他从加州大学欧文分校获得生物科学学士学位，从芝加哥大学获得生物化学和分子生物学博士学位和金融MBA。
- Pratik Shah,has served as a member of Ars Pharmaceuticals, Inc. Board of Directors and Ars Pharmaceuticals, Inc. Chair since the closing of the Merger in November 2022. Dr. Shah previously served on the board of directors of Private ARS Pharma from April 2016 to November 2022 and was appointed as its first Chair of the board of directors in September 2018. Dr. Shah has also served as the Executive Chair and member of the board of directors for Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company, since December 2017, and as President of Marlinspike Group, LLC, since August 2018, and of Marlinspike Group Inc. from June 2015 to October 2020. Dr. Shah served as the Chair of the board of directors of Synthorx, Inc. (formerly Nasdaq: THOR), a clinical-stage biotechnology company, from October 2018 until its acquisition by Sanofi S.A. in January 2020. Dr. Shah also served as the President and Chief Executive Officer and Chair of the board of directors of Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX), biopharmaceutical company, from October 2013 until its acquisition by Teva Pharmaceutical Industries Ltd. in May 2015. From 2004 to 2014 he was a partner at Thomas, McNerney & Partners, a healthcare venture capital firm. Dr. Shah holds a B.S in Biological Sciences from the University of California at Irvine and a Ph.D. in Biochemistry and Molecular Biology and an M.B.A. in Finance, both from the University of Chicago.
- Peter Kolchinsky
-
Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
Peter Kolchinsky has served as a director since January 2015. Dr. Kolchinsky is a founder and Managing Partner of RA Capital, a multi stage investment manager which is dedicated to evidence based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics, services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr. Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly traded biopharmaceutical company, since August 2021, in addition to serving as a member of the board of directors of a number of privately held companies. He is the founder and currently serves on the advisory board of the non profit organization, No Patient Left Behind. Dr. Kolchinsky previously served as a member of the board of directors of Forma Therapeutics Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, Research Alliance Corporation I from April 2020 to June 2021, Research Alliance Corporation II from July 2020 to December 2022, and Synthorx, Inc., from May 2018 to January 2020, all of which were publicly traded biopharmaceutical companies. Dr. Kolchinsky also leads RA Capital's engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor's degree in Biology from Cornell University. - Peter Kolchinsky，他是一名博士，自2021年3月起担任Icosavax, Inc.的董事。他自2013年7月在Therapeutics Acquisition Corp.担任董事。自2004年9月，他在RA Capital公司担任创始合伙人和证券投资经理。他在个人和公共投资领域都十分活跃，投资领域涉及制药、医疗设备、诊断和生命科学工具行业。他编写了一本名为《生物技术入门的经营者指南》的电子书籍，并在American Fertility Association公司担任董事。目前，他在CellScape 公司、Zipline Medical公司、Lantos Technologies公司、Periphagen公司、Calimmune公司和 PiloFocus这六家公司担任董事。他曾在国家科学院（National Academies of Sciences）的全球科技委员会任职。他在哈佛大学（Harvard University）获得病毒学博士学位，并在美国康乃尔大学（Cornell University）获得学士学位。
- Peter Kolchinsky has served as a director since January 2015. Dr. Kolchinsky is a founder and Managing Partner of RA Capital, a multi stage investment manager which is dedicated to evidence based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics, services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr. Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly traded biopharmaceutical company, since August 2021, in addition to serving as a member of the board of directors of a number of privately held companies. He is the founder and currently serves on the advisory board of the non profit organization, No Patient Left Behind. Dr. Kolchinsky previously served as a member of the board of directors of Forma Therapeutics Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, Research Alliance Corporation I from April 2020 to June 2021, Research Alliance Corporation II from July 2020 to December 2022, and Synthorx, Inc., from May 2018 to January 2020, all of which were publicly traded biopharmaceutical companies. Dr. Kolchinsky also leads RA Capital's engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of "The Great American Drug Deal" and "The Entrepreneur's Guide to a Biotech Startup", and frequently writes and speaks on the future of biotechnology innovation. Dr. Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor's degree in Biology from Cornell University.
高管简历
中英对照 | 中文 | 英文- Kathleen Scott
Kathleen Scott将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Scott女士目前是Neurana Pharmaceuticals，Inc.（一家私人生物技术公司）的首席财务官。在Neurana之前，Scott女士从2014年8月到2021年4月担任Recros Medica Health的首席财务官，从2016年2月到2021年3月担任Clarify Medical公司的董事，从2014年8月到2016年12月担任Oncternal Therapeutics公司的董事，从2016年3月到2016年5月担任McRevena公司的董事，从2014年8月到2016年8月以及2010年3月至2014年11月的生物盈余。在加入BioSurplus之前，Scott女士是RA Capital Advisors的合伙人，这是一家圣地亚哥的私人投资银行，提供财务咨询服务。从1994年12月到2010年7月，Scott女士在RA Capital Advisors工作了15年多，为广泛的公司客户完成了数十亿美元的合并、收购、资产剥离和重组。Scott女士的职业生涯始于在Arthur Andersen’；的圣地亚哥办事处担任审计员，专注于公共和私人客户。Scott女士是圣迭戈县基督教青年会的董事会主席，是注册会计师和CFA特许持有人。斯科特女士以优异成绩从加州大学洛杉矶分校毕业，获得经济学/商学学士学位。
Kathleen Scott became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Ms. Scott is currently the Chief Financial Officer of ARS Pharmaceuticals, Inc., a publicly traded biotech company (Nasdaq: SPRY). Prior to ARS Pharmaceuticals, Ms. Scott was the Chief Financial Officer of Neurana Pharmaceuticals from January 2017 to March 2022, Recros Medica from August 2014 to April 2021, Adigica Health from February 2016 to March 2021, Clarify Medical from August 2014 to December 2016, Oncternal Therapeutics from March 2016 to May 2016, MDRejuvena from August 2014 to August 2016, and BioSurplus from March 2010 to November 2014. Prior to BioSurplus, Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. Ms. Scott spent over 15 years with RA Capital Advisors, from December 1994 to July 2010, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen's San Diego office, focusing on both public and private clients. Ms. Scott was the past board chair and is a current director of the YMCA of San Diego County. In September of 2023 Ms. Scott became a director of NKGen Biotech, Inc. (OTCQX: NKGN) and is currently the chair of its audit and compensation committees. Ms. Scott is a CPA and CFA charter holder and graduated magna cum laude from UCLA with a B.S. in economics/business.- Kathleen Scott将在本招股说明书所包含的注册声明生效后立即加入我们的董事会。Scott女士目前是Neurana Pharmaceuticals，Inc.（一家私人生物技术公司）的首席财务官。在Neurana之前，Scott女士从2014年8月到2021年4月担任Recros Medica Health的首席财务官，从2016年2月到2021年3月担任Clarify Medical公司的董事，从2014年8月到2016年12月担任Oncternal Therapeutics公司的董事，从2016年3月到2016年5月担任McRevena公司的董事，从2014年8月到2016年8月以及2010年3月至2014年11月的生物盈余。在加入BioSurplus之前，Scott女士是RA Capital Advisors的合伙人，这是一家圣地亚哥的私人投资银行，提供财务咨询服务。从1994年12月到2010年7月，Scott女士在RA Capital Advisors工作了15年多，为广泛的公司客户完成了数十亿美元的合并、收购、资产剥离和重组。Scott女士的职业生涯始于在Arthur Andersen’；的圣地亚哥办事处担任审计员，专注于公共和私人客户。Scott女士是圣迭戈县基督教青年会的董事会主席，是注册会计师和CFA特许持有人。斯科特女士以优异成绩从加州大学洛杉矶分校毕业，获得经济学/商学学士学位。
- Kathleen Scott became a director upon the effectiveness of Dermata Therapeutics, Inc.'s initial public offering in August 2021. Ms. Scott is currently the Chief Financial Officer of ARS Pharmaceuticals, Inc., a publicly traded biotech company (Nasdaq: SPRY). Prior to ARS Pharmaceuticals, Ms. Scott was the Chief Financial Officer of Neurana Pharmaceuticals from January 2017 to March 2022, Recros Medica from August 2014 to April 2021, Adigica Health from February 2016 to March 2021, Clarify Medical from August 2014 to December 2016, Oncternal Therapeutics from March 2016 to May 2016, MDRejuvena from August 2014 to August 2016, and BioSurplus from March 2010 to November 2014. Prior to BioSurplus, Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. Ms. Scott spent over 15 years with RA Capital Advisors, from December 1994 to July 2010, completing billions of dollars of mergers, acquisitions, divestitures, and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen's San Diego office, focusing on both public and private clients. Ms. Scott was the past board chair and is a current director of the YMCA of San Diego County. In September of 2023 Ms. Scott became a director of NKGen Biotech, Inc. (OTCQX: NKGN) and is currently the chair of its audit and compensation committees. Ms. Scott is a CPA and CFA charter holder and graduated magna cum laude from UCLA with a B.S. in economics/business.
- Sarina Tanimoto
Sarina Tanimoto是Ars Pharmaceuticals，Inc.的联合创始人，自2018年起担任Ars Pharmaceuticals，Inc.首席医疗官，自2015年起担任该职位。2015年至2018年，谷本博士担任Ars Pharmaceuticals，Inc.董事会成员。Tanimoto博士此前曾担任医药产品开发咨询公司Pacific-Link Regulatory Consulting and Research，Inc.的首席医疗官，在那里她支持了多个治疗领域从1期到3期临床试验的多个项目，包括几种鼻内产品。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Tanimoto博士在生物制药公司ANGES Inc.任职期间担任过临床和业务发展方面的职务，还曾在研究型医疗保健公司罗氏（Roche）担任临床科学家，在那里她参与了全球临床开发。谷本博士在富山大学获得医学博士学位，随后在东京国立全球健康和医学中心接受内科培训。她拥有麦吉尔大学的工商管理硕士学位。
Sarina Tanimoto is Ars Pharmaceuticals, Inc. co-founder and has served as Ars Pharmaceuticals, Inc. Chief Medical Officer since 2018, a position she has functionally served in since 2015. From 2015 to 2018, Dr. Tanimoto served as a member of Ars Pharmaceuticals, Inc. Board of Directors. Dr. Tanimoto previously served as Chief Medical Officer of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy, where she supported multiple programs from Phase 1 to Phase 3 clinical trials in various therapeutic areas, including several intranasal products. Prior to Pacific-Link Regulatory Consulting and Research, Inc., Dr. Tanimoto held roles in clinical and business development during her tenure at AnGes Inc., a biopharmaceutical company, and also served as a clinical scientist at Roche, a research healthcare company, where she was involved in global clinical development. Dr. Tanimoto earned an M.D. from University of Toyama, followed by internal medicine training at the National Center for Global Health and Medicine in Tokyo. She holds an M.B.A. from McGill University.- Sarina Tanimoto是Ars Pharmaceuticals，Inc.的联合创始人，自2018年起担任Ars Pharmaceuticals，Inc.首席医疗官，自2015年起担任该职位。2015年至2018年，谷本博士担任Ars Pharmaceuticals，Inc.董事会成员。Tanimoto博士此前曾担任医药产品开发咨询公司Pacific-Link Regulatory Consulting and Research，Inc.的首席医疗官，在那里她支持了多个治疗领域从1期到3期临床试验的多个项目，包括几种鼻内产品。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Tanimoto博士在生物制药公司ANGES Inc.任职期间担任过临床和业务发展方面的职务，还曾在研究型医疗保健公司罗氏（Roche）担任临床科学家，在那里她参与了全球临床开发。谷本博士在富山大学获得医学博士学位，随后在东京国立全球健康和医学中心接受内科培训。她拥有麦吉尔大学的工商管理硕士学位。
- Sarina Tanimoto is Ars Pharmaceuticals, Inc. co-founder and has served as Ars Pharmaceuticals, Inc. Chief Medical Officer since 2018, a position she has functionally served in since 2015. From 2015 to 2018, Dr. Tanimoto served as a member of Ars Pharmaceuticals, Inc. Board of Directors. Dr. Tanimoto previously served as Chief Medical Officer of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy, where she supported multiple programs from Phase 1 to Phase 3 clinical trials in various therapeutic areas, including several intranasal products. Prior to Pacific-Link Regulatory Consulting and Research, Inc., Dr. Tanimoto held roles in clinical and business development during her tenure at AnGes Inc., a biopharmaceutical company, and also served as a clinical scientist at Roche, a research healthcare company, where she was involved in global clinical development. Dr. Tanimoto earned an M.D. from University of Toyama, followed by internal medicine training at the National Center for Global Health and Medicine in Tokyo. She holds an M.B.A. from McGill University.
- Richard E. Lowenthal
Richard E. Lowenthal曾担任Pacific-Link Regulatory Consulting and Research，Inc.的总裁，这是一家由Lowenthal先生创立的医药产品开发咨询公司，在那里他就临床开发、监管事务、质量保证、许可和投资机会提供领导和指导，包括支持Valtoco（地西泮鼻喷剂）的临床和监管开发。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Lowenthal先生曾在多家生物制药和制药公司担任过多个领导职务，包括MTG Biotherapeutics Inc.的首席执行官兼总裁；Cadence Pharmaceuticals, Inc.的法规事务和质量保证副总裁；Maxim Pharmaceuticals，Inc.的全球法规事务、质量保证和药物安全负责人；Anges、MG的法规事务和质量保证副总裁，Inc.；杨森研究基金会全球项目负责人和监管事务全球总监；Somerset Pharmaceticals Inc.监管事务和质量保证总监；美国食品药品监督管理局神经药理药物产品司和肿瘤学和肺部药物产品司新药审查化学家。Lowenthal先生拥有佛罗里达州立大学有机化学硕士学位和圣地亚哥大学行政领导商业科学硕士学位。他曾担任美国药学科学家协会（圣地亚哥地区）前任主席，也是USP生物技术专家委员会、病毒学工作组成员，国家罕见病组织企业理事会成员，曾与多个PhRMA和ICH工作组合作。
Richard E. Lowenthal served as President of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy founded by Mr. Lowenthal, where he provided leadership and mentoring on clinical development, regulatory affairs, quality assurance, licensing and investment opportunities, including supporting the clinical and regulatory development of Valtoco (diazepam nasal spray). Prior to Pacific- Link Regulatory Consulting and Research, Inc., Mr. Lowenthal held many leadership roles at several biopharmaceutical and pharmaceutical companies that included Chief Executive Officer and President of MTG Biotherapeutics Inc.; Vice President of Regulatory Affairs and quality assurance for Cadence Pharmaceuticals, Inc.; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director of Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance for Somerset Pharmaceuticals Inc.; and New Drug Review Chemist for the U.S. Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products. Mr. Lowenthal holds an M.Sc. in organic chemistry from Florida State University and a Master's in Business Science for Executive Leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhRMA and ICH Working Groups.- Richard E. Lowenthal曾担任Pacific-Link Regulatory Consulting and Research，Inc.的总裁，这是一家由Lowenthal先生创立的医药产品开发咨询公司，在那里他就临床开发、监管事务、质量保证、许可和投资机会提供领导和指导，包括支持Valtoco（地西泮鼻喷剂）的临床和监管开发。在加入Pacific-Link Regulatory Consulting and Research，Inc.之前，Lowenthal先生曾在多家生物制药和制药公司担任过多个领导职务，包括MTG Biotherapeutics Inc.的首席执行官兼总裁；Cadence Pharmaceuticals, Inc.的法规事务和质量保证副总裁；Maxim Pharmaceuticals，Inc.的全球法规事务、质量保证和药物安全负责人；Anges、MG的法规事务和质量保证副总裁，Inc.；杨森研究基金会全球项目负责人和监管事务全球总监；Somerset Pharmaceticals Inc.监管事务和质量保证总监；美国食品药品监督管理局神经药理药物产品司和肿瘤学和肺部药物产品司新药审查化学家。Lowenthal先生拥有佛罗里达州立大学有机化学硕士学位和圣地亚哥大学行政领导商业科学硕士学位。他曾担任美国药学科学家协会（圣地亚哥地区）前任主席，也是USP生物技术专家委员会、病毒学工作组成员，国家罕见病组织企业理事会成员，曾与多个PhRMA和ICH工作组合作。
- Richard E. Lowenthal served as President of Pacific-Link Regulatory Consulting and Research, Inc., a medicinal product development consultancy founded by Mr. Lowenthal, where he provided leadership and mentoring on clinical development, regulatory affairs, quality assurance, licensing and investment opportunities, including supporting the clinical and regulatory development of Valtoco (diazepam nasal spray). Prior to Pacific- Link Regulatory Consulting and Research, Inc., Mr. Lowenthal held many leadership roles at several biopharmaceutical and pharmaceutical companies that included Chief Executive Officer and President of MTG Biotherapeutics Inc.; Vice President of Regulatory Affairs and quality assurance for Cadence Pharmaceuticals, Inc.; Head of Worldwide Regulatory Affairs, Quality Assurance and Drug Safety for Maxim Pharmaceuticals, Inc.; Vice President of Regulatory Affairs and Quality Assurance for AnGes, MG, Inc.; Global Project Leader and Global Director of Regulatory Affairs for Janssen Research Foundation; Director of Regulatory Affairs and Quality Assurance for Somerset Pharmaceuticals Inc.; and New Drug Review Chemist for the U.S. Food and Drug Administration in the Division of Neuropharmacologic Drug Products and the Division of Oncology and Pulmonary Drug Products. Mr. Lowenthal holds an M.Sc. in organic chemistry from Florida State University and a Master's in Business Science for Executive Leadership from the University of San Diego. He has served as past chair of the American Association of Pharmaceutical Scientists (San Diego region), as well as member of the USP Biotechnology Expert Committee, Virology Working group, member of the National Organization of Rare Disease Corporate Council and has worked with various PhRMA and ICH Working Groups.
- Eric Karas
Eric Karas，自2022年11月合并完成以来一直担任Ars Pharmaceuticals，Inc.首席商务官。Karas先生自2022年4月起担任Private ARS Pharma的首席商务官。2018年10月至2022年3月，Karas先生在Emergent BioSolutions Inc.（NYSE：EBS）担任北美副总裁兼商业总经理。在此之前，从2016年12月到2018年10月，Karas先生在Adapt Pharma，Inc.领导了NARCAN 鼻喷雾剂的商业计划，该公司于2018年被Emergent BioSolutions收购。在加入Adapt Pharma之前，Karas先生在Auxilium Pharmaceuticals，Inc.工作了八年，负责监督与其泌尿科产品组合相关的所有全球商业目标。他还领导了针对Peyronie病的XIAFLEX 的上市准备规划和上市策略。Auxilium Pharmaceuticals于2015年被远藤制药 PLC（纳斯达克：ENDP）收购。Karas先生还曾在Astellas Pharma Inc.、百时美施贵宝公司（NYSE：BMY）和默克制药公司（NYSE：MRK）担任政府事务、公共关系、患者宣传和销售领导职务等跨职能职务。行业协会认可他针对医疗保健专业人士和消费者开展的无数疾病意识和品牌活动。Karas先生在密歇根州立大学、布罗德管理学院获得综合管理硕士学位，并在罗格斯大学获得会计学学士学位。
Eric Karas,has served as Ars Pharmaceuticals, Inc. Chief Commercial Officer since the closing of the Merger in November 2022. Mr. Karas has served as the Chief Commercial Officer of Private ARS Pharma since April 2022. From October 2018 to March 2022, Mr. Karas served as Vice President and General Manager of Commercial, North America at Emergent BioSolutions Inc. (NYSE: EBS). Prior to that, from December 2016 to October 2018, Mr. Karas led commercial initiatives for NARCAN Nasal Spray at Adapt Pharma, Inc., which was acquired by Emergent BioSolutions in 2018. Prior to Adapt Pharma, Mr. Karas spent eight years at Auxilium Pharmaceuticals, Inc. overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX for Peyronie's disease. Auxilium Pharmaceuticals was acquired in 2015 by Endo International plc (Nasdaq: ENDP). Mr. Karas has also held cross-functional roles in government affairs, public relations, patient advocacy and sales leadership roles at Astellas Pharma Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK). Industry associations have recognized him for numerous disease awareness and branded campaigns targeting healthcare professionals and consumers. Mr. Karas received his M.B.A. in integrated management from Michigan State University, Broad School of Management, and a B.S. in accounting from Rutgers University.- Eric Karas，自2022年11月合并完成以来一直担任Ars Pharmaceuticals，Inc.首席商务官。Karas先生自2022年4月起担任Private ARS Pharma的首席商务官。2018年10月至2022年3月，Karas先生在Emergent BioSolutions Inc.（NYSE：EBS）担任北美副总裁兼商业总经理。在此之前，从2016年12月到2018年10月，Karas先生在Adapt Pharma，Inc.领导了NARCAN 鼻喷雾剂的商业计划，该公司于2018年被Emergent BioSolutions收购。在加入Adapt Pharma之前，Karas先生在Auxilium Pharmaceuticals，Inc.工作了八年，负责监督与其泌尿科产品组合相关的所有全球商业目标。他还领导了针对Peyronie病的XIAFLEX 的上市准备规划和上市策略。Auxilium Pharmaceuticals于2015年被远藤制药 PLC（纳斯达克：ENDP）收购。Karas先生还曾在Astellas Pharma Inc.、百时美施贵宝公司（NYSE：BMY）和默克制药公司（NYSE：MRK）担任政府事务、公共关系、患者宣传和销售领导职务等跨职能职务。行业协会认可他针对医疗保健专业人士和消费者开展的无数疾病意识和品牌活动。Karas先生在密歇根州立大学、布罗德管理学院获得综合管理硕士学位，并在罗格斯大学获得会计学学士学位。
- Eric Karas,has served as Ars Pharmaceuticals, Inc. Chief Commercial Officer since the closing of the Merger in November 2022. Mr. Karas has served as the Chief Commercial Officer of Private ARS Pharma since April 2022. From October 2018 to March 2022, Mr. Karas served as Vice President and General Manager of Commercial, North America at Emergent BioSolutions Inc. (NYSE: EBS). Prior to that, from December 2016 to October 2018, Mr. Karas led commercial initiatives for NARCAN Nasal Spray at Adapt Pharma, Inc., which was acquired by Emergent BioSolutions in 2018. Prior to Adapt Pharma, Mr. Karas spent eight years at Auxilium Pharmaceuticals, Inc. overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX for Peyronie's disease. Auxilium Pharmaceuticals was acquired in 2015 by Endo International plc (Nasdaq: ENDP). Mr. Karas has also held cross-functional roles in government affairs, public relations, patient advocacy and sales leadership roles at Astellas Pharma Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Merck & Co., Inc. (NYSE: MRK). Industry associations have recognized him for numerous disease awareness and branded campaigns targeting healthcare professionals and consumers. Mr. Karas received his M.B.A. in integrated management from Michigan State University, Broad School of Management, and a B.S. in accounting from Rutgers University.
- Justin Chakma
Justin Chakma，自2022年11月完成合并以来一直担任Ars Pharmaceuticals，Inc.首席商务官。Chakma先生自2019年6月起担任Private ARS Pharma的首席商务官。从2018年5月到2019年5月，Chakma先生在Vedanta Biosciences担任副总裁兼业务发展和战略主管，这是一家开发调节免疫反应药物的生物技术公司。在此之前的2015年11月至2018年5月，他在新基医药公司（原纳斯达克：CELG）（被百时美施贵宝公司收购）担任业务发展高级总监。在加入Celgene之前，Chakma先生曾在Receptos, Inc.（前身为纳斯达克：RCPT）（被Celgene收购）、Auspex Pharmaceuticals, Inc.（前身为纳斯达克：ASPX）（被梯瓦制药 Ltd.收购）以及风险投资公司Thomas，McNerney & Partners）担任生物技术和制药业务发展、融资和投资等职务。Chakma先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位，以及多伦多大学的神经科学和经济学学士学位。
Justin Chakma,has served as Ars Pharmaceuticals, Inc. Chief Business Officer since the closing of the Merger in November 2022. Mr. Chakma has served as the Chief Business Officer of Private ARS Pharma since June 2019. From May 2018 to May 2019, Mr. Chakma served as VP, Head of Business Development and Strategy at Vedanta Biosciences, a biotechnology company developing medicines to modulate immune responses. Before that, from November 2015 to May 2018, he was a Senior Director of Business Development at Celgene Corporation (formerly Nasdaq: CELG) (acquired by Bristol-Myers Squibb Company). Prior to joining Celgene, Mr. Chakma held various roles in biotech and pharmaceutical business development, financing and investments at Receptos, Inc. (formerly Nasdaq: RCPT) (acquired by Celgene), Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX) (acquired by Teva Pharmaceutical Industries Ltd.), and Thomas, McNerney & Partners, a venture capital firm. Mr. Chakma holds an M.B.A. from the Wharton School of the University of Pennsylvania, and bachelor's degrees in neuroscience and economics from the University of Toronto.- Justin Chakma，自2022年11月完成合并以来一直担任Ars Pharmaceuticals，Inc.首席商务官。Chakma先生自2019年6月起担任Private ARS Pharma的首席商务官。从2018年5月到2019年5月，Chakma先生在Vedanta Biosciences担任副总裁兼业务发展和战略主管，这是一家开发调节免疫反应药物的生物技术公司。在此之前的2015年11月至2018年5月，他在新基医药公司（原纳斯达克：CELG）（被百时美施贵宝公司收购）担任业务发展高级总监。在加入Celgene之前，Chakma先生曾在Receptos, Inc.（前身为纳斯达克：RCPT）（被Celgene收购）、Auspex Pharmaceuticals, Inc.（前身为纳斯达克：ASPX）（被梯瓦制药 Ltd.收购）以及风险投资公司Thomas，McNerney & Partners）担任生物技术和制药业务发展、融资和投资等职务。Chakma先生拥有宾夕法尼亚大学沃顿商学院的工商管理硕士学位，以及多伦多大学的神经科学和经济学学士学位。
- Justin Chakma,has served as Ars Pharmaceuticals, Inc. Chief Business Officer since the closing of the Merger in November 2022. Mr. Chakma has served as the Chief Business Officer of Private ARS Pharma since June 2019. From May 2018 to May 2019, Mr. Chakma served as VP, Head of Business Development and Strategy at Vedanta Biosciences, a biotechnology company developing medicines to modulate immune responses. Before that, from November 2015 to May 2018, he was a Senior Director of Business Development at Celgene Corporation (formerly Nasdaq: CELG) (acquired by Bristol-Myers Squibb Company). Prior to joining Celgene, Mr. Chakma held various roles in biotech and pharmaceutical business development, financing and investments at Receptos, Inc. (formerly Nasdaq: RCPT) (acquired by Celgene), Auspex Pharmaceuticals, Inc. (formerly Nasdaq: ASPX) (acquired by Teva Pharmaceutical Industries Ltd.), and Thomas, McNerney & Partners, a venture capital firm. Mr. Chakma holds an M.B.A. from the Wharton School of the University of Pennsylvania, and bachelor's degrees in neuroscience and economics from the University of Toronto.
- Brian T. Dorsey
Brian T. Dorsey，自2014年12月起担任高级副总裁兼首席发展官。他在制药和生物技术行业任职逾20年，对于早期研发药品候选的药监局审批，领导高水平药品开发、监管、质量控制/质量保证。他在制药公司担任多个高管职位，最近于2013年4月至2014年9月间担任Pernix Therapeutics的药品开发高级副总裁；2005年至2013年间担任Somaxon Pharmaceuticals的管理职位，职位渐升；此前担任Baxter Bioscience和Pfizer Global Research and Development的管理职位。他获得了the University of San Diego的行政管理硕士学位和化学学士学位。
Brian T. Dorsey,has served as Ars Pharmaceuticals, Inc. Chief Operating Officer since December 2022 and previously served as Ars Pharmaceuticals, Inc. Senior Vice President of Operations and Project Management from the closing of the Merger in November 2022 to December 2022. From October 2018 to December 2022, Mr. Dorsey served as Private ARS Pharma's Senior Vice President of Operations and Project Management. He has served in the pharmaceutical and biotechnology industries for more than 20 years providing high-level drug development, regulatory and QC/QA leadership of pharmaceutical candidates from early development through FDA approval. Mr. Dorsey is a founding partner at MagnaSci Ventures, a healthcare fund focused on investing in early-stage life science companies. He is a founder of numerous companies including Kalyra Pharmaceuticals, Sorriso Pharmaceuticals and Septum Solutions. Prior to joining the Company, Mr. Dorsey was Chief Development Officer for Apricus BioSciences (Nasdaq: APRI) from December 2014 to October 2018. Mr. Dorsey has also held various senior management positions including Senior Vice President of Research and Development and Chief Compliance Officer of Pernix Therapeutics Holding; Senior Vice President of Technical Operations and Regulatory Affairs for Somaxon Pharmaceuticals; Head of Project Management, Medical Writing and Library Services at Maxim Pharmaceuticals; Head of Biopharmaceutical Project Management of Baxter Bioscience and Manager of Chemistry, Manufacturing, and Control for Chugai Biopharmaceuticals. Mr. Dorsey has held several positions within the Agouron/Warner Lambert/Pfizer organization and has lead development projects in the antiviral, oncology, and ophthalmology therapeutic areas. He serves on the board of directors for Forward Sciences, Forge Therapeutics and Blacksmith Medicines. Mr. Dorsey received his Master of Science in Executive Leadership and his B.A. in chemistry from the University of San Diego.- Brian T. Dorsey，自2014年12月起担任高级副总裁兼首席发展官。他在制药和生物技术行业任职逾20年，对于早期研发药品候选的药监局审批，领导高水平药品开发、监管、质量控制/质量保证。他在制药公司担任多个高管职位，最近于2013年4月至2014年9月间担任Pernix Therapeutics的药品开发高级副总裁；2005年至2013年间担任Somaxon Pharmaceuticals的管理职位，职位渐升；此前担任Baxter Bioscience和Pfizer Global Research and Development的管理职位。他获得了the University of San Diego的行政管理硕士学位和化学学士学位。
- Brian T. Dorsey,has served as Ars Pharmaceuticals, Inc. Chief Operating Officer since December 2022 and previously served as Ars Pharmaceuticals, Inc. Senior Vice President of Operations and Project Management from the closing of the Merger in November 2022 to December 2022. From October 2018 to December 2022, Mr. Dorsey served as Private ARS Pharma's Senior Vice President of Operations and Project Management. He has served in the pharmaceutical and biotechnology industries for more than 20 years providing high-level drug development, regulatory and QC/QA leadership of pharmaceutical candidates from early development through FDA approval. Mr. Dorsey is a founding partner at MagnaSci Ventures, a healthcare fund focused on investing in early-stage life science companies. He is a founder of numerous companies including Kalyra Pharmaceuticals, Sorriso Pharmaceuticals and Septum Solutions. Prior to joining the Company, Mr. Dorsey was Chief Development Officer for Apricus BioSciences (Nasdaq: APRI) from December 2014 to October 2018. Mr. Dorsey has also held various senior management positions including Senior Vice President of Research and Development and Chief Compliance Officer of Pernix Therapeutics Holding; Senior Vice President of Technical Operations and Regulatory Affairs for Somaxon Pharmaceuticals; Head of Project Management, Medical Writing and Library Services at Maxim Pharmaceuticals; Head of Biopharmaceutical Project Management of Baxter Bioscience and Manager of Chemistry, Manufacturing, and Control for Chugai Biopharmaceuticals. Mr. Dorsey has held several positions within the Agouron/Warner Lambert/Pfizer organization and has lead development projects in the antiviral, oncology, and ophthalmology therapeutic areas. He serves on the board of directors for Forward Sciences, Forge Therapeutics and Blacksmith Medicines. Mr. Dorsey received his Master of Science in Executive Leadership and his B.A. in chemistry from the University of San Diego.
- Alexander A. Fitzpatrick
Alexander A. Fitzpatrick，2010年11月成为Verenium的高级副总裁、总顾问兼秘书；此前担任Kintera, Inc.（上市技术公司）的高级副总裁、总顾问兼秘书；在Kintera出售之后继续担任Blackbaud, Inc.主要部门的类似职位；此前担任Vivendi Universal SA的一个部门的战略交易主管；此前担任圣地亚哥Cooley LLP和Latham & Watkins LLP，以及伦敦Rogers & Wells LLP now Clifford Chance的商业、企业和技术部门成员，负责生物技术和其他技术公司、投资银行、风险资本，涉及多项交易，包括大量合作、并购、知识产权事务、许可、融资等方面。他获得了Georgetown University的数学学士学位，和 the University of California, Berkeley的法学博士学位。
Alexander A. Fitzpatrick served as the Executive Vice President, General Counsel and Secretary of Private Evofem from October 2017 until January 2018 and has served as our Executive Vice President, General Counsel and Secretary since January 2018. Mr. Fitzpatrick is responsible for our corporate governance, legal, corporate development, intellectual property and risk management functions. Prior to joining Evofem, Mr. Fitzpatrick served as Chief Legal Officer of Kyriba Corporation from 2014 to 2015 and Senior Vice President, General Counsel, Compliance Officer and Secretary of Verenium Corporation, a publicly traded biotechnology company from 2010 to 2014. Prior to that, Mr. Fitzpatrick served as Senior Vice President,General Counsel and Secretary of Kintera, Inc., a publicly traded technology company. Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a major division of Blackbaud, Inc. Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP now Clifford Chance in London, Mr. Fitzpatrick represented pharmaceutical and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity. Mr. Fitzpatrick received a B.S. in mathematics from Georgetown University and a J.D. from the University of California, Berkeley.- Alexander A. Fitzpatrick，2010年11月成为Verenium的高级副总裁、总顾问兼秘书；此前担任Kintera, Inc.（上市技术公司）的高级副总裁、总顾问兼秘书；在Kintera出售之后继续担任Blackbaud, Inc.主要部门的类似职位；此前担任Vivendi Universal SA的一个部门的战略交易主管；此前担任圣地亚哥Cooley LLP和Latham & Watkins LLP，以及伦敦Rogers & Wells LLP now Clifford Chance的商业、企业和技术部门成员，负责生物技术和其他技术公司、投资银行、风险资本，涉及多项交易，包括大量合作、并购、知识产权事务、许可、融资等方面。他获得了Georgetown University的数学学士学位，和 the University of California, Berkeley的法学博士学位。
- Alexander A. Fitzpatrick served as the Executive Vice President, General Counsel and Secretary of Private Evofem from October 2017 until January 2018 and has served as our Executive Vice President, General Counsel and Secretary since January 2018. Mr. Fitzpatrick is responsible for our corporate governance, legal, corporate development, intellectual property and risk management functions. Prior to joining Evofem, Mr. Fitzpatrick served as Chief Legal Officer of Kyriba Corporation from 2014 to 2015 and Senior Vice President, General Counsel, Compliance Officer and Secretary of Verenium Corporation, a publicly traded biotechnology company from 2010 to 2014. Prior to that, Mr. Fitzpatrick served as Senior Vice President,General Counsel and Secretary of Kintera, Inc., a publicly traded technology company. Following the sale of Kintera, Mr. Fitzpatrick continued to serve in a similar position for a major division of Blackbaud, Inc. Prior to that, as a member of the business, corporate and technology departments with the law firms Cooley LLP and Latham & Watkins LLP in San Diego, and Rogers & Wells LLP now Clifford Chance in London, Mr. Fitzpatrick represented pharmaceutical and other technology companies, investment banks and venture capitalists in a variety of transactions including numerous collaborations, mergers and acquisitions, intellectual property matters, licensing and financing activity. Mr. Fitzpatrick received a B.S. in mathematics from Georgetown University and a J.D. from the University of California, Berkeley.